The relationship between androgens, regulators of collagen metabolism, and peyronie's disease: A case control study

Journal of Sexual Medicine

Volumn 7, Issue 12, 2010, Pages 4011-4017

  Karavitakis, Markos ^a   Komninos, Christos ^a   Simaioforidis, Vasileios ^a   Kontos, Stylianos ^a   Lefakis, George ^a   Politis, Vasilios ^a   Koritsiadis, George ^a   Konstantellou, Katerina ^a   Doumanis, Gregorios ^a  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Androgens; Collagen Metabolism; Dehydroepiandrosterone Sulfate; Peyronie's Disease

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; COLLAGEN; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; HUMAN; MALE; PATHOGENESIS; PEYRONIE DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

EID: 78649877659     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01915.x     Document Type: Article

References (40)

1. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146:1007-9.
2. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, De Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23.
3. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-3.
4. Taylor FL, Levin AL. Peyronie's disease. Urol Clin N Am 2007;34:517-34.
5. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009;6(3 suppl):353-62.
6. Somers KD, Sismour EN, Wright GL Jr, Devine CJ Jr, Gilbert DA, Horton CE. Isolation and characterization of collagen in Peyronie's disease. J Urol 1989;141:629-31.
7. Magee TR, Qian A, Rajfer J, Sander FC, Levine LA, Gonzalez-Cadavid NF. Gene expression profiles in the Peyronie's disease plaque. Urology 2002;59:451-7.
8. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008;179:2447-55.
9. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
10. Tallant C, Marrero A, Gomis-Ruth FX. Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim Biophys Acta 2009;1803:20-8.
11. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003;144:1656-63.
12. Bratland A, Ragnhildstveit E, Bjornland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin Exp Metastasis 2003;20:541-7.
13. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: Pilot data suggesting a significant relationship. J Sex Med 2009;6:1729-35.
14. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989;84:640-6.
15. Suh DY, Hunt TK, Spencer EM. Insulin-like growth factor-I reverses the impairment of wound healing induced by corticosteroids in rats. Endocrinology 1992;131:2399-403.
16. Ritvos O, Ranta T, Jalkanen J, Suikkari AM, Voutilainen R, Bohn H, Rutanen EM. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 1988;122:2150-7.
17. Matrisian LM. Matrix metalloproteinase gene expression. Ann N Y Acad Sci 1994;732:42-50.
18. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
19. Rajfer J, Namkung PC, Petra PH. Identification, partial characterization and age-related changes of a cytoplasmic androgen receptor in the rat penis. J Steroid Biochem 1980;13:1489-92.
20. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-501.
21. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997;15:21-6.
22. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
23. Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003;5:33-6.
24. Ferrer JE, Velez JD, Herrera AM. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2009; Sep 29 [Epub ahead of print] doi: 10.1111/j.1743-6109.2009.01508.x
25. Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412-7.
26. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-8.
27. Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabchi AE, Buster JE, Givens JR. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988;66:1329-31.
28. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57-61.
29. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994;79:1086-90.
30. Rhoden EL, Riedner CE, Fuchs S, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to peyronie's disease. J Sex Med 2010;7:1529-37.
31. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 2006;38:89-116.
32. Lee KS, Oh KY, Kim BC. Effects of dehydroepiandrosterone on collagen and collagenase gene expression by skin fibroblasts in culture. J Dermatol Sci 2000;23:103-10.
33. Shin MH, Rhie GE, Park CH, Kim KH, Cho KH, Eun HC, Chung JH. Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin. J Invest Dermatol 2005;124:315-23.
34. Calvo E, Luu-The V, Morissette J, Martel C, Labrie C, Bernard B, Bernerd F, Deloche C, Chaussade V, Leclaire J, Labrie F. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol 2008;112:186-93.
35. Sakyo K, Ito A, Mori Y. Effects of dehydroepiandrosterone sulphate on the production of collagenase and gelatinolytic metalloproteinase by rabbit uterine cervical cells in primary cultures. J Pharmacobiodyn 1986;9:276-86.
36. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, De Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-84.
37. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-505.
38. Clore JN. Dehydroepiandrosterone and body fat. Obes Res 1995;3(4 suppl):613S-6S.
39. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J (Engl) 2002;115:402-4.
40. Coleman DL, Schwizer RW, Leiter EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 1984;33:26-32.